Page 52 - Haematologica April 2020

J. Perez Botero et al.
References
1. Commentary on and reprint of Glanzmann E, Hereditäre häemorrhagische thrombas- thenie. Ein Beitrag zur Pathologie der Blutplättchen [Hereditary hemorrhagic thrombasthenia: A contribution on the pathology of blood platelets], in Jahrbuch für Kinderheilkunde (1918) 88:113–141. In: Lichtman MA, Spivak JL, Boxer LA, Shattil SJ, Henderson ES, eds. Hematology. San Diego: Academic Press, 2000:55-III.
2. Caen J, Cousin C. ["In vivo" disorder of platelet adhesiveness in Willebrand's disease and Glanzmann's thrombasthenias. Trial interpretation]. Nouv Rev Fr Hematol. 1962;2:685-694.
3. Caen JP, Castaldi PA, Leclerc JC, et al Congenital bleeding disorders with long bleeding time and normal platelet count: I. Glanzmann's thrombasthenia (report of fif- teen patients). Am J Med. 1966;41(1):4-26.
4. Nurden AT, Caen JP. An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia. Br J Haematol. 1974;28(2):253-260.
5. Phillips DR, Agin PP. Platelet membrane defects in Glanzmann's thrombasthenia. Evidence for decreased amounts of two major glycoproteins. J Clin Invest. 1977;60(3):535-545.
6. Disorders NOfR. NORD Resource Guide Orphan Disease Update [Newsletter] 2019 April 8, 2019 [cited 2019 April 22]; Available from: https://rarediseases.org
7. Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood. 2011;118(23):5996- 6005.
8. Toogeh G, Sharifian R, Lak M, Safaee R, Artoni A, Peyvandi F. Presentation and pat- tern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. Am J Hematol. 2004;77(2):198-199.
9. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood. 1990;75(7):1383- 1395.
10. Marder VJ. Hemostasis and Thrombosis: Basic Principles and Clinical Practice: Wolters Kluwer Health, 2012.
11. Coller BS, Shattil SJ. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood. 2008;112(8):3011-3025.
12. Coller BS, Seligsohn U, Peretz H, Newman PJ. Glanzmann thrombasthenia: new insights from an historical perspective. Semin Hematol. 1994;31(4):301-311.
13. Nurden AT, Pillois X. ITGA2B and ITGB3 gene mutations associated with Glanzmann thrombasthenia. Platelets. 2018;29(1):98- 101.
14. Richards S, Aziz N, Bale S, et al. Standards
and guidelines for the interpretation of sequence variants: a joint consensus recom- mendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424.
15. Kashiwagi H, Kunishima S, Kiyomizu K, et al. Demonstration of novel gain-of-function mutations of alphaIIbbeta3: association with macrothrombocytopenia and glanz- mann thrombasthenia-like phenotype. Mol Genet Genomic Med. 2013;1(2):77-86.
16. Bury L, Malara A, Gresele P, Balduini A. Outside-in signalling generated by a consti- tutively activated integrin alphaIIbbeta3 impairs proplatelet formation in human megakaryocytes. PLoS One. 2012;7(4): e34449.
17. Nurden AT, Nurden P. Congenital platelet disorders and understanding of platelet func- tion. Br J Haematol. 2014;165(2):165-178.
18. Lowe GC, Lordkipanidze M, Watson SP, UK GAPP study group. Utility of the ISTH bleeding assessment tool in predicting platelet defects in participants with suspect- ed inherited platelet function disorders. J Thromb Haemost. 2013;11(9):1663-1668.
19. Harrison P. The role of PFA-100 testing in the investigation and management of haemosta- tic defects in children and adults. Br J Haematol. 2005;130(1):3-10.
20. Gresele P, Subcommittee on Platelet Physiology of the International Society on T, Hemostasis. Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH. J Thromb Haemost. 2015;13(2):314-322.
from: https://www.clinicalgenome.org/
29. Grainger JD, Thachil J, Will AM. How we treat the platelet glycoprotein defects; Glanzmann thrombasthenia and Bernard Soulier syndrome in children and adults. Br J
Haematol. 2018;182(5):621-632.
30. Inc NN. NovoSeven RT [package insert].
Plainsboro, NJ; 2019.
31. Poon MC, D'Oiron R, Von Depka M, et al.
Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost. 2004;2(7):1096-1103.
32. Poon MC, d'Oiron R, Zotz RB, et al. The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention. Haematologica. 2015;100(8):1038-1044.
33. Poon MC, Di Minno G, d'Oiron R, Zotz R. New Insights Into the Treatment of Glanzmann Thrombasthenia. Transfus Med Rev. 2016;30(2):92-99.
34. Fiore M, Firah N, Pillois X, Nurden P, Heilig R, Nurden AT. Natural history of platelet antibody formation against alphaIIbbeta3 in a French cohort of Glanzmann thrombas- thenia patients. Haemophilia. 2012;18(3): e201-209.
35. Siddiq S, Clark A, Mumford A. A systematic review of the management and outcomes of pregnancy in Glanzmann thrombasthenia. Haemophilia. 2011;17(5):e858-869.
36. Bellucci S, Damaj G, Boval B, et al. Bone marrow transplantation in severe Glanzmann's thrombasthenia with antiplatelet alloimmunization. Bone Marrow Transplant. 2000;25(3):327-330.
37. Ramzi M, Dehghani M, Haghighat S, Nejad HH. Stem Cell Transplant in Severe Glanzmann Thrombasthenia in an Adult Patient. Exp Clin Transplant. 2016;14(6):688-
21. Al Ghaithi R, Drake S, Watson SP, Morgan
NV, Harrison P. Comparison of multiple
electrode aggregometry with lumi-aggre-
gometry for the diagnosis of patients with
mild bleeding disorders. J Thromb Haemost. 2017;15(10):2045-2052. 690.
22. Miller JL. Glycoprotein analysis for the diag- nostic evaluation of platelet disorders. Semin Thromb Hemost. 2009;35(2):224- 232.
23. Kuijpers TW, van de Vijver E, Weterman MA, et al. LAD-1/variant syndrome is caused by mutations in FERMT3. Blood. 2009;113(19):4740-4746.
24. Westbury SK, Canault M, Greene D, et al. Expanded repertoire of RASGRP2 variants responsible for platelet dysfunction and severe bleeding. Blood. 2017;130(8):1026- 1030.
25. Tholouli E, Hay CR, O'Gorman P, Makris M. Acquired Glanzmann's thrombasthenia without thrombocytopenia: a severe acquired autoimmune bleeding disorder. Br J Haematol. 2004;127(2):209-213.
26. Nurden AT. Acquired Glanzmann throm- basthenia: From antibodies to anti-platelet drugs. Blood Rev. 2019;36:10-22.
27. Nurden AT. Glanzmann thrombasthenia. Orphanet J Rare Dis. 2006;1:10.
28. Resource CG. [cited 2019 May 2]; Available
38. Nurden AT, Pillois X, Wilcox DA. Glanzmann thrombasthenia: state of the art and future directions. Semin Thromb Hemost. 2013;39(6):642-655.
39. Bolton-Maggs PH, Chalmers EA, Collins PW, et al. A review of inherited platelet dis- orders with guidelines for their management on behalf of the UKHCDO. Br J Haematol. 2006;135(5):603-633.
40. Wilcox DA, Olsen JC, Ishizawa L, et al. Megakaryocyte-targeted synthesis of the integrin beta(3)-subunit results in the pheno- typic correction of Glanzmann thrombas- thenia. Blood. 2000;95(12):3645-3651.
41. Fang J, Hodivala-Dilke K, Johnson BD, et al. Therapeutic expression of the platelet-spe- cific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia. Blood. 2005;106(8):2671-2679.
42. Sullivan SK, Mills JA, Koukouritaki SB, et al. High-level transgene expression in induced pluripotent stem cell-derived megakary- ocytes: correction of Glanzmann thrombas- thenia. Blood. 2014;123(5):753-757.
894
haematologica | 2020; 105(4)